The use of rizatriptan in the treatment of acute, multiple migraine attacks.
Where this comes from
- Record sourced from PubMed, PMID 11089514.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapy for migraine can be classified as preventive or acute. Preventive therapy is intended to reduce the frequency of headache, whereas the goal of acute migraine therapy is to optimize the patient's ability to function by reversing, aborting, or reducing pain and migraine-associated symptoms. Rizatriptan is a new, selective 5-HT1B/1D receptor agonist that is effective for treatment of migraine. Clinical studies of this drug have demonstrated its efficacy, safety, and tolerability when used as therapy for acute attacks on multiple occasions.